Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • March 13, 2019 11:10 AM | Deleted user

    March 13, 2019, CNN via WebMD 

    The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer. The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported.

    Read more.

  • March 13, 2019 10:51 AM | Deleted user

    March 13, 2019, UDaily  

    Two University of Delaware researchers have developed a new approach to attack cancer, using two light-activated treatments that appear to be more effective together than when applied independently. More research is needed, but the findings point to promising new approaches against an especially challenging kind of cancer — triple negative breast cancer — which was the focus of their recent studies.  

    Read more.

  • March 13, 2019 10:49 AM | Deleted user

    March 13, 2019, Duke Cancer Institute  

    A vaccine developed by Duke Cancer Institute researchers has shown early promise in targeting the HER2 protein that fuels a deadly form of breast cancer. In a phase 1 clinical trial that enrolled 22 women with recurrent cancers that over express the HER2 protein, the vaccine demonstrated an ability to halt tumor growth, and improve survival for a subset of patients. A phase 2 trial is being planned at Duke. 

    Read more.

  • March 11, 2019 10:44 AM | Deleted user

    March 11, 2019, MedPage Today  

    Low-income women enrolled in high-deductible health plans delayed chemotherapy treatments for breast cancer by nearly 9 months versus low-income women enrolled in low-deductible plans, researchers reported. 

    Read more.

  • March 08, 2019 8:57 AM | Deleted user

    March 8, 2019, MedPage Today  

    SEATTLE – Women presenting late in pregnancy with HIV infection were successfully treated with integrase inhibitors in randomized trials, reducing circulating virus faster than efavirenz-based therapy, researchers reported here. 

    Read more.

  • March 08, 2019 8:49 AM | Deleted user

    March 8, 2019, Endocrine Today 

    Adults with hepatitis C who are treated with direct-acting antiviral therapy are less likely to develop diabetes than those who are treated with pegylated interferon/ribavirin or untreated, according to findings presented at the Conference on Retroviruses and Opportunistic Infections 2019 in Seattle. 

    Read more.

  • March 07, 2019 9:26 AM | Deleted user

    March 7, 2019, MedPage Today  

    SEATTLE -- Prior intravenous drug use and hepatitis C infection were tied to increased syphilis rates in women with HIV, factors that could help guide screening decisions in this high-risk group, a new study found. 

    Read more.

  • March 06, 2019 8:43 AM | Deleted user

    March 6, 2019, MedPage Today 

    An artificial intelligence (AI) system performed very similarly to 101 radiologists in detecting breast cancer on digital mammography (DM), a large multi-center, cancer-enriched study of mammograms found. 

    Read more.

  • March 06, 2019 8:41 AM | Deleted user

    March 6, 2019, JAAPA 

    Women with opioid use disorder who become pregnant are a particularly vulnerable population and require a comprehensive treatment approach for mother and fetus. Research is continuing on opioid use disorder, effects of opioid use on the fetus, and best treatment approaches. This article reviews current recommendations and guidelines for treatment.

    Read more.

  • March 05, 2019 8:31 AM | Deleted user

    March 5, 2019, MedPage Today 

    Most cases of cervical cancer worldwide could be eliminated at the end of this century if the human papilloma virus (HPV) vaccination and screening efforts are rapidly expanded, researchers suggest.

    Read more

Powered by Wild Apricot Membership Software